Ascendis Pharma Completes $187.5 Million Sale of Priority Review Voucher

On June 17, 2026, Ascendis Pharma A/S announced the completion of the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for $187.5 million in cash. The transaction was made to an undisclosed buyer and the proceeds are reported before transaction-related expenses. The PRV was originally awarded to Ascendis by the U.S. Food and Drug Administration (FDA) in February 2026 following the approval of YUVIWEL® (navepegritide). This filing confirms the closing of the previously announced sale, providing the company with a significant non-dilutive capital infusion. The report also notes that this Form 6-K will be incorporated by reference into several of the company's existing registration statements on Form S-8 and Form F-3. No further clinical trial updates or changes to the company's pipeline were disclosed in this specific filing.